Key result
The cloned vaccine virus rMLVB was safe, induced high neutralizing antibody titers, and reduced viremia and virus shedding upon heterologous EAV challenge in horses.
A stable full-length cDNA clone of the MLV vaccine strain of EAV was successfully developed, showing identical in vitro characteristics to the parental strain and providing partial clinical protection in vivo, enabling future marker vaccine development.
Facilitates marker vaccine strategies for EAV; clinical adoption in horses awaits confirmatory trials.
A stable full-length cDNA clone of the modified live virus (MLV) vaccine strain of equine arteritis virus (EAV) was developed. RNA transcripts generated from this plasmid (pEAVrMLV) were infectious upon transfection into mammalian cells, and the resultant recombinant virus (rMLV) had 100% nucleotide identity to the parental MLV vaccine strain of EAV. A single silent nucleotide substitution was introduced into the nucleocapsid gene (pEAVrMLVB), enabling the cloned vaccine virus (rMLVB) to be distinguished from parental MLV vaccine as well as other field and laboratory strains of EAV by using an allelic discrimination real-time reverse transcription (RT)-PCR assay. In vitro studies revealed that the cloned vaccine virus rMLVB and the parental MLV vaccine virus had identical growth kinetics and plaque morphologies in equine endothelial cells. In vivo studies confirmed that the cloned vaccine virus was very safe and induced high titers of neutralizing antibodies against EAV in experimentally immunized horses. When challenged with the heterologous EAV KY84 strain, the rMLVB vaccine virus protected immunized horses in regard to reducing the magnitude and duration of viremia and virus shedding but did not suppress the development of signs of EVA, although these were reduced in clinical severity. The vaccine clone pEAVrMLVB could be further manipulated to improve the vaccine efficacy as well as to develop a marker vaccine for serological differentiation of EAV naturally infected from vaccinated animals.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2012) studied Equine arteritis virus (EAV) infection. Cloned vaccine virus rMLVB vs. Parental MLV vaccine virus was evaluated on Safety, neutralizing antibodies, and protection against heterologous EAV challenge. The cloned vaccine virus rMLVB was safe, induced high neutralizing antibody titers, and reduced viremia and virus shedding upon heterologous EAV challenge in horses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: